肿瘤M2-PK和NSE联检在小细胞肺癌诊断中的价值

目的：探讨肿瘤M2型丙酮酸激酶（Tumor M2-PK）和神经元特异性烯醇化酶（NSE）在小细胞肺癌（SCLC）早期诊断中的价值。方法：采用酶联免疫吸附法和电化学发光免疫分析仪（Eleesys2010）分别检测32例SCLC患者及50例肺良性疾病患者外周血中Tumor M2-PK和NSE的含量。结果：SCLC患者Tumor M2-PK和NSE水平明显高于肺良性疾病患者，差异有统计学意义（P〈0．01）。单个检测Tumor M2-PK、NSE及联检Tumor M2-PK和NSE（Tumor M2-PK＋NSE）的敏感性分别为46．9％（15／32）、59．4％（19／32）及68．8％（22／32），特异性分别为92％（46／50）、90％（45／50）及84％（42／50）。结论：Tumor M2-PK和NSE对于小细胞肺癌的辅助诊断有一定的临床意义。联检Tumor M2-PK和NSE可提高小细胞肺癌的诊断敏感性。

Diagnosis Value of Combined Detection of Plasma Tumor M2-PK and Serum NSE Levels in Patients with Small Cell Lung Cancer

Objective To investigate the diagnostic value of determination of plasma tumor M2-PK and serum NSE levels in patients with small cell lung cancer(SCLC).Methods Plasma tumor M2-PK(with ELISA) and serum NSE(with CLIA) levels were determined in 32 patients with SCLC and 50 patients with benign lung disorders(as controls).Results The plasma levels of tumor M2-PK and serum levels of NSE were significantly higher in SCLC group than in patients with benign lung diseases(P<0.01).The sensitivity of tumor M2-PK NSE and combined tumor M2-PK and NSE for diagnosis of SCLC was 46.9%,59.4% and 68.8% respectively,and the specificity was 92%,90% and 84% respectively.Conclusion Tumor M2-PK and NSE are valuable markers for diagnosis of SCLC.Combined measurement of tumor M2-PK and NSE can improve diagnostic sensitivity,which is helpful to early diagnosis.